DNMT3A and acute myeloid leukemia: In patients with IR‐AML, besides those with mutations in FLT3‐ITD (60.0% vs. 84.5%, P = .026) or DNMT3A (59.1% vs. 85.4%, P = .014), patients with mutant RUNX1 (42.9% vs. 82.5%, P = .029) had a significantly lower rate of CR than those with wild type.